|
OmniComm Systems, Inc. Is Chosen By Valeant Pharmaceuticals International For Electronic Data Capture
Major pharmaceutical company chooses the TrialMaster® EDC solution due to a clear distinction in superior services and support
FT. LAUDERDALE, FL - January 7, 2008 - /MarketWire/ - OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that following a rigorous evaluation of six electronic data capture vendors, OmniComm's TrialMaster software was selected by Valeant Pharmaceuticals as its first choice for EDC. The initial vendor evaluation began with six EDC companies that quickly narrowed down to two major players. TrialMaster's user-friendly, intuitive and feature rich functionality were important elements in the final decision, but OmniComm's customer referrals for superior service and customer support became the deciding factor.
"Companies like Valeant demand and deserve not only first-class software solutions for their clinical research studies, but they must also have superior technical and clinical support for their implementation to successfully benefit from this technology," said Cornelis F. Wit, CEO of OmniComm Systems. "Our customers all have unique needs when it comes to support of EDC and we are committed to providing service that satisfies those needs. The high praise that we have received from our customers fuels our commitment to deliver second to none support services for Valeant and all of our customers."
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.
OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. OmniComm Systems Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.
Valeant Pharmaceuticals International is a global specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, infectious disease and dermatology. Through its global infrastructure, Valeant develops and commercializes important treatments for patients worldwide. Valeant focuses promotional efforts on eleven promoted products, but also has a number of other successful regional products throughout the world.
Safe Harbor Disclaimer
Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.
CONTACT:
Lizanne Kelley
OmniComm Systems, Inc.
954-473-1254 Extension 283
lkelley@omnicomm.com
Back
|
